| Primary |
| Drug Use For Unknown Indication |
20.6% |
| Prophylaxis |
14.2% |
| Hypertension |
7.6% |
| Onychomycosis |
7.4% |
| Bronchopulmonary Aspergillosis |
6.0% |
| Product Used For Unknown Indication |
5.8% |
| Pneumonia |
4.6% |
| Nail Tinea |
4.3% |
| Febrile Neutropenia |
4.1% |
| Acute Lymphocytic Leukaemia |
2.9% |
| Acute Myeloid Leukaemia |
2.9% |
| Oral Candidiasis |
2.9% |
| Constipation |
2.7% |
| Lymphoma |
2.6% |
| Diabetes Mellitus |
2.4% |
| Insomnia |
2.2% |
| Gastric Ulcer |
2.0% |
| Fungal Infection |
1.7% |
| Sepsis |
1.6% |
| Multiple Myeloma |
1.5% |
|
| Pyrexia |
11.2% |
| Interstitial Lung Disease |
10.7% |
| White Blood Cell Count Increased |
9.2% |
| White Blood Cell Count Decreased |
8.9% |
| Weight Increased |
6.8% |
| Pneumonia |
5.9% |
| Renal Impairment |
5.6% |
| Drug Interaction |
4.4% |
| Electrocardiogram Qt Prolonged |
4.1% |
| Myalgia |
3.6% |
| Oedema Peripheral |
3.6% |
| Respiratory Failure |
3.6% |
| Malaise |
3.3% |
| Ileus |
3.0% |
| Vomiting |
3.0% |
| Blood Creatine Phosphokinase Increased |
2.7% |
| Pleural Effusion |
2.7% |
| Pseudoaldosteronism |
2.7% |
| Renal Failure Acute |
2.7% |
| Rhabdomyolysis |
2.7% |
|
| Secondary |
| Drug Use For Unknown Indication |
16.2% |
| Prophylaxis |
10.8% |
| Pneumonia |
7.4% |
| Hypertension |
6.9% |
| Bronchopulmonary Aspergillosis |
6.1% |
| Fungal Infection |
5.8% |
| Product Used For Unknown Indication |
5.4% |
| Cardiac Failure |
4.3% |
| Systemic Lupus Erythematosus |
4.3% |
| Febrile Neutropenia |
4.1% |
| Gastric Ulcer |
3.9% |
| Insomnia |
3.2% |
| Acute Myeloid Leukaemia |
2.9% |
| Extranodal Nk/t-cell Lymphoma, Nasal Type |
2.9% |
| Oral Candidiasis |
2.8% |
| Cough |
2.7% |
| Constipation |
2.7% |
| Bronchitis Chronic |
2.6% |
| Sepsis |
2.5% |
| Bronchiectasis |
2.4% |
|
| White Blood Cell Count Increased |
17.1% |
| Interstitial Lung Disease |
10.5% |
| Respiratory Failure |
8.7% |
| White Blood Cell Count Decreased |
6.6% |
| Pyrexia |
6.3% |
| Renal Failure |
5.2% |
| Renal Impairment |
5.2% |
| Weight Increased |
4.9% |
| Pseudoaldosteronism |
4.5% |
| Renal Disorder |
4.5% |
| Systemic Mycosis |
3.5% |
| Gamma-glutamyltransferase Increased |
3.1% |
| Liver Disorder |
2.8% |
| Pulmonary Alveolar Haemorrhage |
2.8% |
| Blood Glucose Increased |
2.4% |
| Myalgia |
2.4% |
| Platelet Count Decreased |
2.4% |
| Pneumonia |
2.4% |
| Azoospermia |
2.1% |
| Oedema Peripheral |
2.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
21.8% |
| Prophylaxis |
21.7% |
| Drug Use For Unknown Indication |
16.0% |
| Infection Prophylaxis |
6.1% |
| Multiple Myeloma |
4.7% |
| Aplastic Anaemia |
4.4% |
| Myelodysplastic Syndrome |
2.8% |
| Neoplasm Malignant |
2.7% |
| Pneumonia |
2.5% |
| Antifungal Prophylaxis |
2.0% |
| Hypertension |
1.9% |
| Stem Cell Transplant |
1.8% |
| Acute Lymphocytic Leukaemia |
1.8% |
| Bronchopulmonary Aspergillosis |
1.7% |
| Iron Overload |
1.5% |
| Constipation |
1.4% |
| Insomnia |
1.4% |
| Rheumatoid Arthritis |
1.4% |
| Atypical Mycobacterial Infection |
1.2% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.2% |
|
| White Blood Cell Count Decreased |
26.6% |
| Renal Impairment |
9.7% |
| Pneumonia |
7.2% |
| Sepsis |
7.2% |
| Platelet Count Decreased |
6.6% |
| Pyrexia |
5.3% |
| Vomiting |
4.7% |
| Thrombocytopenia |
4.2% |
| Neutrophil Count Decreased |
3.3% |
| White Blood Cell Count Increased |
3.3% |
| Febrile Neutropenia |
2.8% |
| Liver Disorder |
2.8% |
| Death |
2.5% |
| Interstitial Lung Disease |
2.2% |
| Septic Shock |
2.2% |
| Malignant Neoplasm Progression |
1.9% |
| Neuropathy Peripheral |
1.9% |
| Renal Disorder |
1.9% |
| Ventricular Tachycardia |
1.9% |
| Hepatic Function Abnormal |
1.7% |
|
| Interacting |
| Prophylaxis |
14.5% |
| Fungal Infection |
12.2% |
| Acute Lymphocytic Leukaemia |
10.7% |
| Prophylaxis Against Gastrointestinal Ulcer |
7.6% |
| Systemic Lupus Erythematosus |
7.6% |
| Neoplasm Malignant |
6.1% |
| Antifungal Prophylaxis |
4.6% |
| Hypertension |
4.6% |
| Oral Candidiasis |
4.6% |
| Constipation |
3.8% |
| Diabetes Mellitus |
3.8% |
| Plasma Cell Myeloma |
3.8% |
| Infection Prophylaxis |
3.1% |
| Diarrhoea |
2.3% |
| Drug Use For Unknown Indication |
2.3% |
| Lupus Nephritis |
2.3% |
| Dermatophytosis |
1.5% |
| Histiocytosis Haematophagic |
1.5% |
| Interstitial Lung Disease |
1.5% |
| Lymphoma |
1.5% |
|
| Systemic Mycosis |
27.8% |
| White Blood Cell Count Decreased |
22.2% |
| Hepatic Steatosis |
11.1% |
| Memory Impairment |
11.1% |
| Oedema Peripheral |
5.6% |
| Renal Impairment |
5.6% |
| Trichophytosis |
5.6% |
| Ureteric Rupture |
5.6% |
| Urinary Retention |
5.6% |
|
